Eisenstadt Richard I
Known title: Chief Financial OfficerCIK: 0001515806
Eisenstadt Richard I's purchase track record
Eisenstadt Richard I has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/24/2023 | ALT | $43K | -9.5% | -39.6% | +8.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ALT | ▲ Buy | Grant | 4,621 | $12K | 1/31/2024 | View on chart |
| ALT | ▲ Buy | Option Exercise | 9,275 | $0 | 1/30/2024 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 2,175 | $21K | 1/30/2024 | View on chart |
| ALT | ▲ Buy | Option Exercise | 12,500 | $0 | 12/29/2023 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 3,044 | $34K | 12/29/2023 | View on chart |
| ALT | ▲ Buy | Grant | 1,825 | $5K | 7/31/2023 | View on chart |
| ALT | ▲ Buy | Open Market | 10,000 | $43K | 3/24/2023 | View on chart |
| ALT | ▲ Buy | Grant | 1,172 | $12K | 1/31/2023 | View on chart |
| ALT | ▲ Buy | Option Exercise | 12,500 | $0 | 12/31/2022 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 3,028 | $50K | 12/31/2022 | View on chart |
| ALT | ▲ Buy | Grant | 1,366 | $9K | 7/31/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Altimmune to attend Wells Fargo healthcare conference
Altimmune has been confirmed as a participant in the Wells Fargo 21st Annual Healthcare Conference. The company joins a roster of healthcare firms presenting at the event, which is a common venue for biopharma companies to engage with investors and outline pipeline progress. No new clinical, regulatory, or financial announcements accompanied the participation news, so the development is a routine scheduling item rather than a fundamental catalyst. As context, the stock has been trading well below the average analyst price target of $17.22, with its 52-week range between $2.56 and $6.44.
Altimmune to attend Wells Fargo healthcare conference. Altimmune has been confirmed as a participant in the Wells Fargo 21st Annual Healthcare Conference. The company joins a roster of healthcare firms presenting at the event, which is a common venue for biopharma companies to engage with investors and outline pipeline progress. No new clinical, regulatory, or financial announcements accompanied the participation news, so the development is a routine scheduling item rather than a fundamental catalyst. As context, the stock has been trading well below the average analyst price target of $17.22, with its 52-week range between $2.56 and $6.44.